A5069614323- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- RNA and protein synthesis mechanisms
- Cancer, Hypoxia, and Metabolism
- Advanced biosensing and bioanalysis techniques
- HER2/EGFR in Cancer Research
- Metastasis and carcinoma case studies
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chemokine receptors and signaling
- RNA modifications and cancer
- Hematological disorders and diagnostics
- Mesenchymal stem cell research
- Cancer, Lipids, and Metabolism
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- 3D Printing in Biomedical Research
- Microfluidic and Bio-sensing Technologies
- Chronic Myeloid Leukemia Treatments
The University of Texas MD Anderson Cancer Center
2014-2024
Rutgers, The State University of New Jersey
2022-2023
Creative Commons
2023
Huntsville Hospital
2022
Environmental and Occupational Health Sciences Institute
2022
Lankenau Medical Center
2020
University of Iowa Hospitals and Clinics
2015-2018
Fox Chase Cancer Center
2012
National Cancer Institute
2012
University of Naples Federico II
2012
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of is complex. Natural killer (NK) that have been modified to express an anti-CD19 potential overcome these limitations.
Currently, there is extensive information about circulating tumor cells (CTC) and their prognostic value; however, little known other characteristics of these cells. In this prospective study, we assessed the gene transcripts epithelial-to-mesenchymal transition-inducing transcription factors (EMT-TF) cancer stem cell (CSC) features in patients with HER2(+) metastatic breast (MBC). Epithelial were enriched from peripheral blood mononuclear (PBMC) using antibody-coated anti-CD326 antibody...
Epithelial cancer cells are likely to undergo epithelial-mesenchymal transition (EMT) prior entering the peripheral circulation. By undergoing EMT, circulating tumor (CTCs) lose epithelial markers and may escape detection by conventional methods. Therefore, we conducted a pilot study investigate mRNA transcripts of EMT-inducing transcription factors (TFs) in from blood (PB) patients with primary breast (PBC). PB mononuclear were isolated 52 stages I-III PBC 30 healthy donors (HDs)...
Traditional factors currently used for prognostic stratification do not always adequately predict treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy monitoring. In this retrospective study, we explored role CTC counts predictors patients with limited metastatic dissemination.A total 492 who had count assessed by CellSearch prior to...
Inflammatory breast cancer (IBC) is the most insidious form of locally advanced cancer; about a third patients have distant metastasis at initial staging. Emerging evidence suggests that host factors in tumor microenvironment may interact with underlying IBC cells to make them aggressive. It unknown whether immune associated play role this scenario transiently promote epithelial mesenchymal transition (EMT) these cells. We hypothesized soluble secreted by activated can induce an EMT and thus...
Abstract BACKGROUND: The significance of circulating tumor cells (CTCs) in blood and disseminated (DTCs) bone marrow (BM) patients with early stage breast cancer is unclear. In this study, the authors investigated occurrence CTCs DTCs women evaluated correlation their presence other prognostic markers. METHODS: Blood BM aspirations were collected at time primary surgery. detected by using CellSearch assay, immunostaining aspirates for pancytokeratin. was correlated classification (T1 vs T2),...
Introduction Altered serum microRNA (miRNA) levels may be correlated with a dysregulated expression pattern in parental tumor tissue and reflect the clinical evolution of disease. The overexpression miR-21, miR-10b, miR-19a is associated acquisition malignant characteristics (increased cell proliferation, migration, invasion, dissemination, metastasis); thus, we determined their utility as biomarkers for aggressive breast cancer (HER2-overexpressed or -amplified [HER2+] inflammatory [IBC])....
Abstract BACKGROUND: Lenalidomide, an immunomodulatory agent, has activity in lymphoproliferative disorders. The authors, therefore, evaluated its effects on T‐cell immunophenotype and cytokine production patients with chronic lymphocytic leukemia (CLL). METHODS: To study the of lenalidomide CLL, authors recruited 24 untreated CLL enrolled a phase 2 clinical trial obtained peripheral blood specimens for immunologic studies consisting enumeration T cells assessing their ability to synthesize...
Circulating tumor cells (CTCs) play a crucial role in dissemination and are prognostic primary metastatic breast cancer. Peripheral blood (PB) immune contribute to an unfavorable microenvironment for CTC survival. This study aimed correlate CTCs with the PB T-cell immunophenotypes functions of patients inflammatory cancer (IBC).This included 65 IBC treated at MD Anderson Cancer Center. was obtained from prior starting new line chemotherapy enumeration by CellSearch(®), T cell phenotype...
Increasing research suggests that inflammation mediates symptom development. In this longitudinal study, we examined inflammatory factors related to the development of high burden during autologous hematopoietic stem cell transplant (AuSCT) for multiple myeloma. Patients (n = 63) repeatedly reported severity on MD Anderson Symptom Inventory myeloma module (MDASI-MM) and contributed blood samples periodically up 100 days after AuSCT marker assays. The temporal associations between serum...
Inflammatory breast cancer (IBC), the most aggressive subtype, is driven by an immunosuppressive tumor microenvironment (TME). Current treatments for IBC have limited efficacy. In a clinical trial (NCT01036087), anti-EGFR antibody combined with neoadjuvant chemotherapy produced highest pathological complete response rate ever reported in patients having triple-negative receptor status. We determined molecular and immunological mechanisms behind this superior outcome. Using novel humanized...
Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a surrogate source material that can be obtained via venipuncture (also known liquid biopsy) and used to better understand characteristics. However, only FDA-cleared CTC assay has been limited enumeration surface marker-defined not further characterization CTCs. In this study, we tested ability semi-automated device capable capturing harvesting CTCs peripheral based on cell size deformability, agnostic...
The Parsortix® PC1 system, Food and Drug Administration (FDA) cleared for use in metastatic breast cancer (MBC) patients, is an epitope-independent microfluidic device the capture harvest of circulating tumor cells from whole blood based on cell size deformability. This report details analytical characterization linearity, detection limit, precision, reproducibility this device.System performance was determined using K2-EDTA samples collected self-declared healthy female volunteers (HVs) MBC...
Abstract Background Since the first suggestion of prospectively identifiable cancer stem cells in solid tumors, efforts have been made to characterize reported cell surrogates existing lines, and lines rich with these used screen for targeted agents. Although 293T were derived from human embryonic kidney, transplantation into mammary fat pad yields aggressive tumors that self-renew as evidenced by serial xenograft passages through transplantation. Herein we fully cell-like features kidney...
Objectives: To determine the effects of thalidomide and placebo on anorexia-cachexia its related symptoms, body composition, resting metabolic rate, serum cytokines their receptors in patients with advanced cancer. Methods: Included study were cancer weight loss greater than 5% 6 months who reported anorexia, fatigue, one following: anxiety, depression, or sleep disturbances. Patients chemotherapy within 2 weeks prior during excluded from study. randomly assigned to either 100 mg once a day...
Background: Circulating tumor cells (CTCs) are an independent prognostic factor in metastatic breast cancer (MBC) patients treated by conventional dose chemotherapy.The aim of this study was to determine the role CTCs and undergoing epithelial-mesenchymal transition (EMT) cancer.We used platform high-dose chemotherapy (HDCT) autologous hematopoietic stem cell transplantation (AHSCT) with EMT.Patients methods: were enumerated 21 MBC before apheresis 1 month after AHSCT.CD34-depleted products...
// Michal Mego 1, 5 , Hui Gao 1 Evan N. Cohen Simone Anfossi Antonio Giordano 10 Sanda Tin Tamer M. Fouad 2, 6 Ugo De Giorgi 7 Mario Giuliano 8 Wendy A. Woodward 3, 4 Ricardo H. Alvarez Vicente Valero Naoto T. Ueno Gabriel Hortobagyi 2 Massimo Cristofanilli 9 and James Reuben Department of Hematopathology, The University Texas MD Anderson Cancer Center, Houston, TX, USA Breast Medical Oncology, 3 Radiation Morgan Welch Inflammatory Research Program Clinic, Currently at Comenius University,...
Both constitutive secretion and Ca(2+)-regulated exocytosis require the assembly of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes. At present, little is known about how SNARE complexes mediating these two distinct pathways differ in structure. Using Drosophila neuromuscular synapse as a model, we show that mutation modifying hydrophobic layer syntaxin 1A regulates rate vesicle fusion. Syntaxin molecules share highly conserved threonine C-terminal +7...
Abstract BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous leukemia (CML). In majority of patients, imatinib induces a complete cytogenetic response (CCyR); however, molecular responses are infrequent. The Bcr‐Abl fusion creates unique sequence amino acids that could constitute target immunomodulation. METHODS: A mixture heteroclitic and native peptides derived from both b3a2 b2a2 sequences was used to vaccinate patients with CML in CCyR who were...
Purpose: Sodium stibogluconate (SSG), a small molecule inhibitor of protein tyrosine phosphatases, combined with IFN-alpha-2b (IFN-α) inhibited solid tumor cell line growth in vitro.We conducted phase I clinical trial SSG plus IFN-α advanced cancer patients to assess tolerance, maximum tolerated dose (MTD) and immune system effects.Experimental Design: was administered intravenously alone for five days week 1, cycle 1 (21 per cycle) together 2b s (3 million units sc TIW) 2, after rest during...